Yingqi Investment

Total investments

2

Average round size

20M

Portfolio companies

2

Exits

1

Areas of investment
Health CareMedicalClinical Trials

Summary

The usual cause for the fund is to invest in rounds with 5 partakers. The meaningful sponsors for the fund in investment in the same round are Xiamen Changrong Investment Management, Ming Bioventures, JMCR Partners.

The high activity for fund was in 2019. The common things for fund are deals in the range of 5 - 10 millions dollars. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 deals per year.

Among the most popular fund investment industries, there are Health Care, Medical. Among the various public portfolio startups of the fund, we may underline Viva Biotech Besides, a startup needs to be aged 11-15 years to get the investment from the fund.

Show more

Investments analytics

Analytics

Total investments
2
Lead investments
0
Exits
1
Investments by industry
  • Clinical Trials (1)
  • Medical (1)
  • Health Care (1)
Investments by region
  • China (2)
Peak activity year
2019

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Group Appearance index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
VivaVision Biotech 26 Sep 2019 Late Stage Venture 10M Shanghai, China
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.